Kisspeptin-10 — Peptide Dosing Protocols reference

patient_educationexpert_opinion · status: needs_provider_review

Details

Author: —

Citation: —

Summary (generated — provider review required)

Kisspeptin Peptide Dosing Guide: Benefits, Dosing, Hormone Effects (2026) Shop Protocols Stacks A–Z Index Email Updates Home Protocols Kisspeptin Protocol Guide - Dosing, Reconstitution & Safety Protocol / Research Dosing Guide Kisspeptin Protocol Guide - Dosing, Reconstitution & Safety Research-context reference for planning kisspeptin protocols: dosing math by form, reconstitution, supplies by cycle, tachyphylaxis boundaries, and safety. Not medical advice. By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Orbitrex Peptides Kisspeptin Supply View Orbitrex Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Kisspeptin Comparisons Related Protocols Blood Tests FAQ References Kisspeptin Quick Start Kisspeptin is a signaling peptide that helps turn on the reproductive hormone pathway.

The original source document remains the source of truth. Generated summaries are not authoritative.

Linked assets (13) · phenotypes (0)

evidence_reference, dosing_reference, mechanism, safety_reference, monitoring_reference

Findings (147) · awaiting review (100)

regulatory · pending

Research status Not FDA-approved.

dosing · pending

By Garret Grant · Founder & Lead Researcher · Last reviewed June 2026 · Share Supplier Pick Copy code PEPPAL Copy code PEPPAL Verified Supplier Verified Supplier Orbitrex Peptides Kisspeptin Supply View Orbitrex Table of Contents View Supplies Quick Start Dosing Protocol & Schedule Supplies Needed Reconstitution Guide Mechanism Who Should Avoid It Side Effects & Safety Timeline & Monitoring Clinical Evidence Storage & Handling Troubleshooting Regulatory Status Kisspeptin Comparisons Related Protocols Blood Tests FAQ References Kisspeptin Quick Start Kisspeptin is a signaling peptide that helps turn on the reproductive hormone pathway.

mechanism · pending

In women, LH and FSH help control ovulation and fertility signals.

dosing · pending

clears fast, with a half-life of about 4 minutes in blood after IV dosing.

dosing · pending

Kisspeptin-54 lasts longer, with a half-life of about 28 minutes after subcutaneous dosing.

dosing · pending

Route Subcutaneous (SC), meaning under the skin, in research-use protocols.

dosing · pending

Measure Use vial concentration (mg/mL) and U-100 syringe units for the dose.

mechanism · pending

Testosterone pathway Kisspeptin may raise testosterone indirectly by raising LH first.

mechanism · pending

Continuous exposure can make the signal fade, a problem called desensitization.

regulatory · pending

No kisspeptin product is FDA-approved.

dosing · pending

Kisspeptin Dosing Protocol & Schedule Choose the form that matches the vial being researched.

dosing · pending

They last for different amounts of time, and the dose math is different.

dosing · pending

Kisspeptin-10 (SC) Kisspeptin-54 (SC) SC means subcutaneous, or under the skin.

dosing · pending

After IV dosing, its blood half-life is about 4 minutes.

dosing · pending

A subcutaneous shot may stretch the effect a little, but the LH and FSH signal is still short.

dosing · pending

That is why research-use protocols usually use small once-daily or twice-daily SC doses instead of long exposure.

dosing · pending

Kisspeptin-10 — Common Research-Context Dosing Ranges Approach Low-dose pulse Typical Range 50-100 mcg Frequency Once daily SC Notes SC means under the skin.

dosing · pending

Approach Standard pulse Typical Range 100-200 mcg Frequency Once daily SC Notes Common community research range, based partly on kisspeptin-54 trial data.

dosing · pending

Approach Split dose Typical Range 100 mcg Frequency Twice daily SC Notes Used when the research plan calls for more frequent LH pulses.

dosing · pending

Approach Typical Range Frequency Notes Low-dose pulse 50-100 mcg Once daily SC SC means under the skin.

dosing · pending

Standard pulse 100-200 mcg Once daily SC Common community research range, based partly on kisspeptin-54 trial data.

dosing · pending

Split dose 100 mcg Twice daily SC Used when the research plan calls for more frequent LH pulses.

dosing · pending

Tachyphylaxis with chronic dosing Continuous exposure can make the LH signal fade.

mechanism · pending

That signal fade is called desensitization or tachyphylaxis.

dosing · pending

After subcutaneous dosing, its blood half-life is about 28 minutes, and LH can stay higher for several hours.

dosing · pending

Trial doses are often listed as nmol/kg, so they do not convert neatly to a simple mcg dose.

mechanism · pending

When the kisspeptin signal is pushed too long, LH response can fade.

dosing · pending

Kisspeptin Supplies Needed Plan based on a simple kisspeptin-10 setup: one 100 mcg subcutaneous dose per day from a 10 mg vial mixed with 2 mL bacteriostatic water.

dosing · pending

lanned draws before losses; 4 weeks: 28 doses needed; one vial provides about 100 planned draws before losses; 6 weeks: 42 doses needed; one vial provides a large margin for priming losses; 8 weeks: 56 doses needed; one vial still leaves margin for losses and schedule adjustments 2-8 weeks 1 vial 2 weeks: 14 doses needed; one vial provides about 100 planned draws before losses; 4 weeks: 28 doses needed; one vial provides about 100 planned draws before losses; 6 weeks: 42 doses needed; one vial provides a large margin for priming losses; 8 weeks: 56 doses needed; one vial still leaves margin for losses and schedule adjustments Insulin Syringes (U-100, 0.3 mL) One syringe per injection.

dosing · pending

Kisspeptin-54 — Reported Trial-Context Dosing Trial Context IVF oocyte maturation trigger (high OHSS risk) Dose Studied 3.2-12.8 nmol/kg single bolus Route Subcutaneous Source/Notes Phase 2 trial in 60 women, Hammersmith Hospital, 2013-2014 Trial Context IVF oocyte maturation trigger (proof-of-concept) Dose Studied 1.6-12.8 nmol/kg single bolus Route Subcutaneous Source/Notes 53-women trial; LH peaked at ~5 hours and returned to pre-trigger by 12-14 hours Trial Context Hypothalamic amenorrhea (chronic SC, twice weekly) Dose Studied 6.4 nmol/kg Route Subcutaneous, twice weekly Source/Notes Reduced response over time consistent with desensitization Trial Context HSDD modulation (women, men) Dose Studied 1 nmol/kg/h IV infusion Route Intravenous, 75-minute infusion Source/Notes Imperial College / Hammersmi

dosing · pending

th trials, 2021-2023 Trial Context Dose Studied Route Source/Notes IVF oocyte maturation trigger (high OHSS risk) 3.2-12.8 nmol/kg single bolus Subcutaneous Phase 2 trial in 60 women, Hammersmith Hospital, 2013-2014 IVF oocyte maturation trigger (proof-of-concept) 1.6-12.8 nmol/kg single bolus Subcutaneous 53-women trial; LH peaked at ~5 hours and returned to pre-trigger by 12-14 hours Hypothalamic amenorrhea (chronic SC, twice weekly) 6.4 nmol/kg Subcutaneous, twice weekly Reduced response over time consistent with desensitization HSDD modulation (women, men) 1 nmol/kg/h IV infusion Intravenous, 75-minute infusion Imperial College / Hammersmith trials, 2021-2023 These are trial protocols, not dosing recommendations.

dosing · pending

Dose conversion depends on body weight.

dosing · pending

For example, 6.4 nmol/kg of kisspeptin-54 is about 2.85 mg for a 70 kg subject.

dosing · pending

Cycle structure and desensitization Kisspeptin Cycle Guidelines Approach Short pulse cycle Active Length 2-4 weeks Off Period 2-4 weeks Reasoning Limits desensitization; aligned with most acute research data Approach Standard cycle Active Length 4-6 weeks Off Period 4 weeks Reasoning Most-cited community window; longer cycles risk fading LH response Approach Diagnostic single use Active Length Single dose Off Period N/A Reasoning Mirrors clinical use as an LH/FSH stimulation test or IVF trigger Approach Active Length Off Period Reasoning Short pulse cycle 2-4 weeks 2-4 weeks Limits dese

dosing · pending

nsitization; aligned with most acute research data Standard cycle 4-6 weeks 4 weeks Most-cited community window; longer cycles risk fading LH response Diagnostic single use Single dose N/A Mirrors clinical use as an LH/FSH stimulation test or IVF trigger Avoid nonstop exposure.

dosing · pending

At that mix, the vial is 5 mg/mL, so 2 units on a U-100 insulin syringe gives 100 mcg.

dosing · pending

If your vial size, water amount, or dose is different, redo the math before drawing.

dosing · pending

Peptide Vials (10 mg kisspeptin-10) Each 10 mg vial reconstituted with 2 mL gives 5 mg/mL; one vial supports approximately 100 doses at 100 mcg.

dosing · pending

Cycle length Planning note 2-8 weeks 1 vial 2 weeks: 14 doses needed; one vial provides about 100 p

Processing

Processed into 27 searchable sections.